Form 8-K

8-K — Nano Dimension Ltd.

Accession: 0001104659-26-075126

Filed: 2026-06-17

Period: 2026-06-16

CIK: 0001643303

SIC: 3672 (PRINTED CIRCUIT BOARDS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2618166d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2618166d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2618166d1_8k.htm · Sequence: 1

false

0001643303

2026-06-16

0001643303

NNDM:AmericanDepositarySharesMember

2026-06-16

0001643303

NNDM:RightsToPurchaseAmericanDepositarySharesMember

2026-06-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

June 16, 2026

NANO

DIMENSION LTD.

(Exact name of registrant as specified in its

charter)

State of Israel

(State or Other Jurisdiction

of Incorporation)

001-37600

52-0029109

(Commission

File Number)

(I.R.S.

Employer Identification No.)

Tower Road

Waltham,

02451

(Address

of Principal Executive Offices)

(Zip

Code)

(866)

496-1805

(Registrant’s Telephone Number, Including

Area Code)

(Former Name or Former Address, If Changed

Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

Written communications pursuant to Rule 425 under

the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under

the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule

14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

Pre-commencement communications pursuant to Rule

13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:

Trading

Symbol:

Name

of Each

Exchange

on Which

Registered:

American

Depositary Shares each representing one Ordinary Share par value NIS 5.00 per share (1)

Ordinary Shares, par value NIS 5.00 per share (2)

NNDM

The Nasdaq

Stock Market LLC

Rights

to Purchase American Depositary Shares, each American Depositary Share representing one

Ordinary Share, par value NIS 5.00 per share

NNDM

The Nasdaq

Stock Market LLC

(1) Evidenced by American Depositary Receipts.

(2) Not for trading, but only in connection with the listing

of the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934

(17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 7.01.

Regulation FD Disclosure.

On June 16, 2026, Nano Dimension Ltd. (“Nano”

or the “Company”) issued a press release to provide additional information regarding its proposed business combination with

Infinite Epigenetics, Inc. (the “Transaction”). A copy of the press release is furnished as Exhibit 99.1 to this current report

on Form 8-K.

The information contained in this Item 7.01 and

in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of Nano, whether made before or after the date

hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing.

The information in this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section

18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)

of the Securities Act of 1933, as amended.

Additional Information and Where to Find It

The Company has filed a preliminary proxy statement

and intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for an extraordinary

general meeting of shareholders that will include, among other proposals, a proposal to approve on a non-binding advisory basis a resolution

regarding the continuation of Nano Dimension’s strategic alternatives review process including any related transaction approved

by the Board (the “Extraordinary General Meeting”). THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE

PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND THE ACCOMPANYING WHITE PROXY CARD WHEN THEY BECOME AVAILABLE, AS THEY WILL

CONTAIN IMPORTANT INFORMATION.

Shareholders may obtain the proxy statement, any

amendments or supplements to the proxy statement and other documents as and when filed by the Company with the SEC without charge from

the SEC’s website at www.sec.gov.

This current report on Form 8-K may be deemed

to be solicitation material in respect of the Transaction. In connection with the Transaction, upon execution of the Definitive Agreement

and pursuant to the terms thereof, Nano expects to file with the SEC a registration statement on Form S-4 that will contain a proxy statement

of Nano that will constitute a prospectus with respect to Nano’s securities to be issued in the Transaction (the “Proxy Statement/Prospectus”).

Nano may also file other documents with the SEC regarding the Transaction. This document is not a substitute for the Proxy Statement/Prospectus

or any other document which Nano may file with the SEC. INVESTORS AND SECURITYHOLDERS OF NANO AND INFINTE ARE URGED TO READ THE PROXY

STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED BY NANO WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS

TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED

MATTERS. Following the execution of the Definitive Agreement, if at all, Nano shareholders and Infinite stockholders will also be able

to obtain free copies of the Proxy Statement/Prospectus (when available) and other documents containing important information about Nano,

Infinite and the Transaction that will be filed with the SEC by Nano through the website maintained by the SEC at www.sec.gov. Following

the execution of the Definitive Agreements, if at all, copies of the documents filed with the SEC by Nano will also be available free

of charge on Nano’s website at https://investors.nano-di.com/sec-filings-1/default.aspx or by contacting Nano’s investor

relations department by email at ir@nano-di.com.

Participants in the Solicitation

The Company, the President, Chief Executive Officer

and Director, David Stehlin, and each of its non-employee directors (namely, Robert Pons; Phillip Borenstein; Dr. Joshua Rosensweig and

Andrew Sriubas) are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the

solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at the Extraordinary General

Meeting. Information about the compensation of our non-employee Directors is set forth in the sections titled “Director Compensation”

and “Director Compensation Table” in the Company’s Annual Report, at pages 54-56, and is available here. Information

about the compensation of our President, Chief Executive Officer, and Director, David Stehlin, is set forth in the section titled “Executive

Compensation” in the Annual Report, at pages 56-64, and is available here. Information regarding the participants’

holdings of the Company’s securities can be found in the section titled “Security Ownership of Certain Beneficial Owners

and Management and Related Shareholder Matters” in the Company’s Annual Report on pages 64-65 and is available here,

and as updated in the filings referenced below. Supplemental information regarding the participants’ holdings of the Company’s

securities can be found in SEC filings on Statements of Change in Ownership on Form 4 filed with the SEC on May 29, 2026 for Mr. Stehlin

(available here) and June 10, 2026 (available here). Such filings are available on the Company’s website at https://investors.nano-di.com/sec-filings-1/default.aspx

or through the SEC’s website via the links referenced above.

Updated information regarding the participants’

direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s preliminary proxy statement on Schedule

14A and will be set forth in the Company’s definitive proxy statement and other materials to be filed with the SEC in connection

with the Extraordinary General Meeting.

Nano and its directors and executive officers

may be deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation

of proxies from Nano’s shareholders in connection with the Transaction. Information regarding the persons who may, under SEC rules,

be deemed participants in the solicitation of proxies from Nano’s shareholders in connection with the Transaction will be set forth

in the Proxy Statement/Prospectus on Form S-4 for the Transaction, which is expected to be filed with the SEC by Nano if Nano and Infinite

enter into the Definitive Agreement. Investors and securityholders of Nano and Infinite are urged to read the Proxy Statement/Prospectus

and other relevant documents that, if Nano and Infinite enter into the Definitive Agreement, will be filed with the SEC by Nano carefully

and in their entirety when they become available because they will contain important information about the Transaction.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release issued by the Company on June 16, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nano Dimension Ltd.

(Registrant)

Date: June 17, 2026

By:

/s/ John Brenton

John Brenton

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2618166d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Nano Dimension and Infinite Epigenetics Provide Additional Information

Regarding Proposed Business Combination

Companies Provide Additional Color on Infinite’s Business

Model, Market Opportunity and Capital Plan, and Respond to Murchinson Ltd.’s Letter

WALTHAM, Mass., June 16,

2026 — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano”, or the “Company”)

and Infinite Epigenetics™ (“Infinite Epigenetics,” “Infinite”) today issued the following

shareholder update to provide additional detail on the proposed business combination announced on June 15, 2026. The Company has

carefully reviewed Murchinson’s recent letter regarding the proposed transaction with Infinite. While we welcome shareholder engagement

and are committed to transparency, the final details of the transaction are still being negotiated. However, we would like to address

specific questions posed by Murchinson, contextualize the Infinite story and commercial success achieved, and provide further perspective

on the substantial value creation of the proposed transaction. We will then provide complete details and a description of the proposed

transaction for discussion with shareholders once finalized. We recognize that this is a complex transaction and appreciate the feedback

that we have received so far; we look forward to continued discussions with shareholders about this transaction with the benefit of full

and finalized information, and the exciting path forward for Nano.

A Real Business with Proven Science in a Well-Established Market

Murchinson's letter ignores the central fact that Nano's Board of Directors

(the “Board”) evaluated: Infinite Epigenetics is not a concept company and not an AI wrapper around generic healthcare data.

It is built on operating businesses, a CLIA-certified methylation laboratory, established science, and defensible proprietary assets,

which is precisely why the Board believes this combination presents a compelling long-term value creation opportunity for shareholders.

The science is established, not speculative.

Epigenetics is one of the most extensively validated areas of modern molecular biology, supported by a deep and growing body of peer-reviewed

research, including over 50 publications authored by experts within Infinite’s team. A single sample processed in Infinite's CLIA-certified

laboratory can read more than one million epigenetic signals, and its proprietary database comprises more than 120,000 biological samples,

among the largest private DNA methylation datasets in the world. This is not a concept awaiting proof. It is an operating diagnostic platform

with existing commercial revenue, a network of more than 7,500 healthcare providers, and issued intellectual property.

The category is proven by public-market

leaders. The model of building a category-defining molecular diagnostics company is well established, and three multi-billion-dollar

public companies have each validated a different piece of what Infinite is building. GRAIL (~$2.5B Market Cap) demonstrated that methylation-based

diagnostics can detect disease. Exact Sciences (valued at ~$21B in announced acquisition by Abbott), with Cologuard, demonstrated that

a molecular diagnostic test can achieve broad clinical adoption and payor reimbursement and scale into a household name. Tempus AI (~$9B

Market Cap) demonstrated that proprietary biological data paired with AI commands a premium public-market valuation. Notably, Brad Keywell,

Original Investor & Board Member of Tempus AI, is the Chairman of Infinite’s board, a reflection of experienced confidence

in Infinite's approach.

Infinite is pursuing all three of these proven strategies: methylation-based

detection, a scaled clinical testing business, and a proprietary data-and-AI platform, simultaneously, on a single platform and across

multiple disease areas. The opportunity these companies illustrate is precisely the one Murchinson overlooks: enormous value is created

as a data-driven diagnostics platform scales, and that value accrues to those who participate early rather than after it has already been

recognized in the public markets. Moreover, by utilizing AI, Infinite can scale its business with a fraction of the capital required

by its predecessors.

Clear Strategic Rationale and Capital Plan

Of the approximately 20 opportunities

that the Nano leadership thoroughly evaluated, Infinite was selected as the single greatest candidate to drive value for Nano’s

shareholders. While Infinite represents a transition of Nano’s operations from 3D printing to AI-powered preventive health and diagnostics,

the Board believes the next wave of healthcare AI will be built on proprietary biological data, not generic medical text, and Infinite's

focus on DNA methylation is a distinct and complementary frontier. The chronic disease diagnostics market exceeds $90 billion, significantly

larger than the 3D printing industry. The Board's focus is on capturing the biggest addressable market for shareholders, which this opportunity

delivers.

Infinite is developing the next step:

a multi-omics foundation model trained in biology rather than language. Its AI strategy begins with a live, provider-facing assistant

that helps clinicians interpret methylation reports today, but the chatbot is merely the interface. The real value sits underneath it,

in the biological foundation model and the IP that powers it: a proprietary dataset, proprietary algorithms, multiple patents, and existing

commercial scale, designed to learn from methylation data and clinical context that cannot be scraped from the internet. This is

the defined purpose of Nano's capital: to accelerate the data, validation, compute, and clinical infrastructure that turn a real diagnostics

business into a compounding biological AI platform, an asset that cannot be easily replicated and grows more valuable over time.

This transaction is not a search for a use of capital, it is a plan

to deploy capital against a specific, defensible asset. The capital would fund two complementary engines of value. First, it would accelerate

commercialization of Infinite's existing diagnostic and consumer operations, expanding the provider network, test volume, and multiple

revenue lines of an already-operating business. Second, it would fund the continued expansion of Infinite's proprietary methylation dataset

and the development of its biological AI platform: the data engine and the models that translate epigenetic signals into earlier detection

of major chronic diseases.

The epigenome records what is happening

in your body right now, governing which genes are turned on or off in response to age, environment, and disease. The AI models that are

currently prominent in computational biology are trained on static gene sequencing and predict average population behavior, not the functional

state of a real person measured over time. Only epigenetic data can do this. Infinite uniquely owns one of the world’s largest epigenetic

datasets with more than 120,000 samples, making it one of the only platforms capable of executing this vision. The result is a compounding

dynamic. Commercial growth generates more proprietary data, that data strengthens the AI platform, and the platform deepens a competitive

advantage that cannot be easily replicated and grows more valuable over time. Unlike genetic testing, which returns the same fixed

result every time, epigenetic testing is dynamic and longitudinal: a patient's biology changes over time, so they can be retested again

and again. That makes it a recurring model rather than a one-time transaction, and every repeat test feeds the model, making it smarter.

Finally, this transaction differs meaningfully from a SPAC. This is

not a situation where the amount of cash at closing is unclear, the capitalization table is over-burdened by warrants and the external

sponsor receives a significant promote. Rather, this transaction reflects a value-accretive combination with a defined operating business.

Unlike a SPAC, the Company remains an operating platform with existing assets, and capital and strategic direction. Further, in the contemplated

transaction, the premium to Nano’s cash value accrues to the benefit of Nano’s shareholders through their ownership in the

combined company, not a SPAC sponsor.

A Rigorous Review and Diligence Process

The term sheet with Infinite is the culmination of a months-long, rigorous

and comprehensive review process conducted with the support of Nano’s financial advisor and legal counsel. This review process considered

a range of opportunities, including companies within the manufacturing space, as well as those operating in healthcare diagnostics, artificial

intelligence, biological data analytics, and precision medicine. In addition, the Company engaged the services of several well-known consultants

to assist in assessing Infinite’s technology, target markets and business operations.

Board Expertise and Independence

The Board is composed of individuals with significant experience across

capital allocation, mergers & acquisitions, corporate governance, public markets and technology-enabled industries. The board

remains committed to driving long-term returns for shareholders and has the ability, with the support of external experts and advisors,

to evaluate complex opportunities and execute transactions that enhance shareholder value.

Additionally, Murchinson's reference to General Garrett conflates two

fundamentally different roles. A director is a fiduciary who votes to approve a transaction; an advisor provides subject-matter expertise

and has no vote, no fiduciary duty, and no authority over whether a deal proceeds or on what terms. General Garrett serves Infinite Epigenetics

as an advisor on government and military health, a field unrelated to the matters Murchinson cites, and plays no role in Nano's evaluation

or approval of this combination, which rests with Nano's Board and its shareholders. Attaching a prior, unanimous Board decision to an

individual's later, unrelated advisory role is innuendo, not analysis.

Alignment with Shareholders

The Board rejects any implication that its decision to pursue this

transaction is motivated by interests that are not aligned with shareholders. For the avoidance of doubt, the Board has not approved and

will not support any arrangement that is not aligned with shareholder interests. Indeed, this transaction will not provide for any separate

or transaction-driven compensation or payouts. The term sheet provides for Nano to get two board seats to join the combined company board

based upon the expected shareholder ownership split; this is designed to protect the ongoing interests of Nano’s shareholders and

is standard practice for all stock mergers.

We have heard from certain shareholders that they prefer a simple return

of capital. That option is far less attractive than it appears. A liquidation or wind-down would not return the headline cash dollar-for-dollar:

it would be reduced materially by wind-down and professional costs, tax leakage, reserves for contingent liabilities, and the time value

of cash escrowed for an extended period before any final distribution. It would also assign zero value to Nano's Nasdaq listing, a scarce,

expensive-to-replicate asset, and remove any chance of upside. By contrast, the proposed combination values Nano at net cash plus a 20%

premium, preserving Nano’s listing's value, lets holders retain contingent value rights on Nano's legacy assets, and adds equity

upside, a premium with optionality versus a discount with finality.

Transaction Terms

While we are not able to address particular terms of the merger until

we have fully negotiated definitive documents, we believe the terms we have negotiated thus far are customary for transactions of this

nature. Moreover, we are affording our shareholders the opportunity to receive a 20% premium for the cash value of the Company through

the ownership in the combined entity.

Market Reaction vs. Long-term Outlook

Short-term trading volatility is not a reliable measure of long-term

value creation as market reactions immediately following an announcement are often incomplete, information-constrained and influenced

by short-term trading dynamics. The Board is committed to clear and consistent engagement with all investors and is confident that once

the full and detailed information is available for review, investors will recognize the substantial value creation opportunity that this

transaction represents. To that end, any definitive agreement will be presented and subject to shareholder vote. The Board does not make

decisions focused on maximizing short-term price performance but rather aligned with strategies that they believe will generate superior

long-term value creation for the Company’s shareholders.

Board Providing Transparency vs. Unclear Alternative From Murchinson

We agree with Murchinson that transparency

is critical to maintaining credibility and the confidence of shareholders. Since Dave Stehlin was named CEO in September 2025 and

the strategic review process was initiated, the Company has issued 13 press releases and updates where possible to ensure that the focus

and strategy of the Board is clear. Our latest announcement, investor call, investor presentation and this subsequent press release are

all testaments to the Board's commitment to provide information to shareholders as available so they can make an informed decision.

While we acknowledge the importance of Murchinson's ability to ask questions, we believe the same standard of transparency should be applied

equally to all parties. Murchinson has requisitioned an extraordinary shareholder meeting with intent to replace a majority of Nano's

Board, yet despite multiple requests and offers for engagement, has not provided any detail on what their plan for Nano would be. On

behalf of all shareholders, we ask: how would they utilize Nano's significant balance sheet reserves? The absence of any such transparency

leaves shareholders without the information needed to evaluate whether Murchinson's intentions are aligned with the best interests of

the Company and all of its shareholders.

Murchinson is asking shareholders to focus on surface-level labels.

Nano is asking shareholders to look at the asset and value potential: a commercial epigenetics diagnostics platform with strong recurring

revenue, a CLIA-certified lab, more than 120,000 epigenetic samples processed, over 50 peer-reviewed validation studies, reported performance

metrics across major chronic diseases that are stronger than traditional diagnostics, one of the world’s largest proprietary biological

datasets, and an AI foundation model that Nano’s capital can help accelerate toward significant revenue growth.

Nano’s cash is not being used to chase an AI slogan. It is expected

to fund clinical validation, payer evidence, reimbursement work, provider growth, data infrastructure, regulatory preparation, pharma

and data partnerships, and disciplined commercial scale.

About Nano Dimension Ltd.

Nano Dimension Ltd. (Nasdaq: NNDM) has

historically delivered advanced digital manufacturing technologies serving customers across the defense, aerospace, automotive, electronics

and medical device industry segments. Following a strategic review process initiated in 2025, the Company has focused on streamlining

its operations, reducing cash burn, monetizing product lines and evaluating opportunities to deploy its capital base and publicly traded

company platform into a more compelling long-term value creation opportunity. Nano Dimension continues to operate its remaining product

lines, while the Company advances its strategic plan and evaluates the proposed business combination with Infinite Epigenetics. For more

information, please visit www.nano-di.com.

About Infinite Epigenetics

Infinite Epigenetics is an AI-powered,

preventive health and diagnostics company building a proprietary biological AI platform to read, interpret, and apply epigenetic signals

at scale. Powered by one of the world’s largest private DNA methylation datasets and supported by a deep body of peer-reviewed

research, the company partners with biotech innovators, researchers, and healthcare organizations to translate epigenetic insights into

actionable diagnostic and clinical applications. Its operating portfolio includes TruDiagnostic™, a CLIA-certified laboratory and

clinical epigenetic testing company, and Tally Health™, a consumer longevity and preventive health company. For more information,

visit www. infiniteepigenetics.com.

infiniteepigenetics.com

trudiagnostic.com

tallyhealth.com

prnewswire.com/news/trudiagnostic

Forward Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the extraordinary

general meeting requisitioned by Murchinson, Nano Dimension’s strategic plan, strategic alternatives review process, expectations

on the timing, economics and success of the proposed business combination, beliefs regarding the future success and long-term growth opportunities

of Infinite Epigenetics and the combined company, expectations for the structure of the proposed business combination, belief that deploying

Nano’s capital and publicly traded company platform into a high growth healthcare and data business offers a more compelling path

to long-term value creation than continuing to scale within the advanced digital manufacturing sector, and all other statements other

than statements of historical fact that address activities, events or developments that Nano Dimension intends, expects, projects, believes

or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as “believe,”

“project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,”

“target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,”

“plan,” “may,” “could,” “should,” “will,” “would,” “continue,”

“likely,” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking

statements. Such statements are based on management’s beliefs and assumptions made based on information currently available to management.

These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results

and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, the Company

cautions shareholders that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions,

estimates and uncertainties that are difficult to predict. The forward-looking statements contained or implied in this communication are

subject to other risks and uncertainties, including, but not limited to (i) the risk that Nano Dimension and Infinite Epigenetics

are unable to negotiate and enter into a definitive agreement for the proposed combination; (ii) the risk that the conditions to

the closing (including any necessary shareholder approvals) are not satisfied; (iii) uncertainties as to the timing of the consummation

of the proposed combination and the ability of each of Nano Dimension and Infinite Epigenetics to consummate the proposed combination;

(iv) effect of the announcement of the proposed combination on the ability of Nano Dimension and Infinite Epigenetics to continue

to operate their respective businesses and retain and hire key personnel and to maintain favorable business relationships; (v) risks

related to the failure or delay in obtaining required approvals from any governmental or regulatory entity necessary to consummate the

proposed combination; (vi) changes in the exchange ratio that could cause Nano Dimension’s shareholders and Infinite Epigenetics’

stockholders to own more or less of the combined company than is currently anticipated; (vii) risks related to the market price of

Nano Dimension’s shares relative to the value suggested by the term sheet; (viii) unexpected costs, charges or expenses resulting

from the proposed combination; (ix) the potential for the occurrence of any event, change or other circumstance or condition that

could give rise to the termination of the definitive agreement for the proposed combination and the other agreements entered into in connection

therewith; (x) the possibility that holders of CVRs may never receive any proceeds therefrom; (xi) changes in demand for Nano

Dimenson’s or Infinite Epigenetics’ products and services; (xii) global market, political and economic conditions, and

conditions in the countries in which Nano Dimension and Infinite Epigenetics operate; (xiii) the impact of changes in law and government

regulations; (xiv) competition in the epigenetics health industry; (xv) the risk of litigation, including any proceedings that

may be instituted against Nano Dimension or Infinite Epigenetics related to the proposed combination; (xvi) the impact of rapid technological

change in the epigenetics health industry; and (xvii) those discussed under the heading “Risk Factors” in Nano Dimension’s

annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission

(the “SEC”) on March 31, 2026, and in any subsequent filings with the SEC.

Except as otherwise required by law, Nano Dimension undertakes no obligation

to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect

the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained

on such websites is not incorporated by reference into this communication.

Additional Information and Where to Find It

The Company has filed a preliminary proxy statement and intends to

file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for an extraordinary general meeting

of shareholders that will include, among other proposals, a proposal to approve on a non-binding advisory basis a resolution regarding

the continuation of Nano Dimension’s strategic alternatives review process including any related transaction approved by the Board

(the “Extraordinary General Meeting”). THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY

STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND THE ACCOMPANYING WHITE PROXY CARD WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN

IMPORTANT INFORMATION.

Shareholders may obtain the proxy statement,

any amendments or supplements to the proxy statement and other documents as and when filed by the Company with the SEC without charge

from the SEC’s website at www.sec.gov.

This communication also relates to a

proposed combination involving Nano Dimension and Infinite Epigenetics and may be deemed to be solicitation material in respect of the

proposed combination. In connection with the proposed combination, Nano Dimension intends to file with the Securities and Exchange Commission

(the “SEC”) a registration statement on Form S-4 that will contain a proxy statement of Nano Dimension that will constitute

a prospectus with respect to shares of Nano Dimension’s stock to be issued in the proposed combination (the “Proxy Statement/Prospectus”).

Nano Dimension may also file other documents with the SEC regarding the proposed combination. This document is not a substitute for the

Proxy Statement/Prospectus or any other document which Nano Dimension may file with the SEC. INVESTORS AND SECURITYHOLDERS OF NANO DIMENSION

AND INFINTE EPIGENETICS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED BY NANO

DIMENSION WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL

CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED COMBINATION AND RELATED MATTERS. Nano Dimension shareholders and Infinite Epigenetics

stockholders will also be able to obtain free copies of the Proxy Statement/Prospectus (when available) and other documents containing

important information about Nano Dimension, Infinite Epigenetics and the proposed combination that will be filed with the SEC by

Nano Dimension through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Nano Dimension

will also be available free of charge on Nano Dimension’s website at https://investors.nano-di.com/sec-filings-1/default.aspx

or by contacting Nano Dimension’s investor relations department by email at ir@nano-di.com.

Participants in the Solicitation

The Company, the President, Chief Executive

Officer and Director, David Stehlin, and each of its non-employee directors (namely, Robert Pons; Phillip Borenstein; Dr. Joshua

Rosensweig and Andrew Sriubas) are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange

Act of 1934) in the solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at

the Extraordinary General Meeting. Information about the compensation of our non-employee Directors is set forth in the sections titled

“Director Compensation” and “Director Compensation Table” in the Company’s Annual Report, at pages 54-56,

and is available here. Information about the compensation of our President, Chief Executive Officer, and Director, David

Stehlin, is set forth in the section titled “Executive Compensation” in the Annual Report, at pages 56-64, and is available

here. Information regarding the participants’ holdings of the Company’s securities can be found in the section titled

“Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters” in the Company’s Annual

Report on pages 64-65 and is available here, and as updated in the filings referenced below. Supplemental information regarding

the participants’ holdings of the Company’s securities can be found in SEC filings on Statements of Change in Ownership on

Form 4 filed with the SEC on May 29, 2026 for Mr. Stehlin (available here) and June 12, 2026 (available here).

Such filings are available on the Company’s website at https://investors.nano-di.com/sec-filings-1/default.aspx or through

the SEC’s website via the links referenced above.

Updated information regarding the participants’ direct or indirect

interests, by security holdings or otherwise, is be set forth in the Company’s preliminary proxy statement on Schedule 14A and

will be set forth in the Company’s definitive proxy statement and other materials to be filed with the SEC in connection with the

Extraordinary General Meeting.

Nano Dimension and its directors and executive officers may be deemed

to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of

proxies from Nano Dimension’s shareholders in connection with the proposed combination. Information regarding the persons who may,

under SEC rules, be deemed participants in the solicitation of proxies from Nano Dimension’s shareholders in connection with the

proposed combination will be set forth in the Proxy Statement/Prospectus on Form S-4 for the proposed combination, which is expected

to be filed with the SEC by Nano Dimension. Investors and securityholders of Nano Dimension and Infinite Epigenetics are urged to read

the Proxy Statement/Prospectus and other relevant documents that will be filed with the SEC by Nano Dimension carefully and in their

entirety when they become available because they will contain important information about the proposed combination.

Contacts

Investors:

Purva Sanariya

Director, Investor Relations

ir@nano-di.com

Media:

Samuel Manning

Principal Manager, External Communications

press@nano-di.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 16, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 16, 2026

Entity File Number

001-37600

Entity Registrant Name

NANO

DIMENSION LTD.

Entity Central Index Key

0001643303

Entity Tax Identification Number

52-0029109

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Tower Road

Entity Address, City or Town

Waltham

Entity Address, State or Province

Entity Address, Postal Zip Code

02451

City Area Code

866

Local Phone Number

496-1805

Written Communications

true

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

American Depositary Shares [Member]

Title of 12(b) Security

American

Depositary Shares

Trading Symbol

NNDM

Security Exchange Name

NASDAQ

Rights To Purchase American Depositary Shares [Member]

Title of 12(b) Security

Rights

to Purchase American Depositary Shares

Trading Symbol

NNDM

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=NNDM_AmericanDepositarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=NNDM_RightsToPurchaseAmericanDepositarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: